Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: Results from a Phase III study

Clinical Endocrinology

Volumn 81, Issue 3, 2014, Pages 408-417

  Pivonello, Rosario ^a   Petersenn, Stephan ^b   Newell Price, John ^c   Findling, James W ^d   Gu, Feng ^e   Maldonado, Mario ^f   Trovato, Andrew ^f   Hughes, Gareth ^f   Salgado, Luiz R ^g   Lacroix, André ^h   Schopohl, Jochen ⁱ   Biller, Beverly M K ^j  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b ENDOC Center for Endocrine Tumors   (Germany)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ UNIVERSITY OF MUNICH   (Germany)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PASIREOTIDE; SOMATOSTATIN;

ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; CUSHING SYNDROME; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE;

CHOLESTEROL; CUSHING SYNDROME; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; SOMATOSTATIN; WAIST CIRCUMFERENCE;

EID: 84905108254     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12431     Document Type: Article

References (33)

1. Pivonello, R., De Martino, M.C., De Leo, M., et al,. (2008) Cushing's syndrome. Endocrinology and Metabolism Clinics of North America, 37, 135-149.
2. Newell-Price, J., Bertagna, X., Grossman, A.B., et al,. (2006) Cushing's syndrome. The Lancet, 367, 1605-1617.
3. Biller, B.M.K., Grossman, A.B., Stewart, P.M., et al,. (2008) Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology & Metabolism, 93, 2454-2462.
4. Webb, S.M., Badia, X., Barahona, M.J., et al,. (2008) Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. European Journal of Endocrinology, 158, 623-630.
5. Sonino, N., &, Fava, G.A., (1998) Psychosomatic aspects of Cushing's disease. Psychotherapy & Psychosomatics, 67, 140-146.
6. van Aken, M.O., Pereira, A.M., Biermasz, N.R., et al,. (2005) Quality of life in patients after long-term biochemical cure of Cushing's disease. Journal of Clinical Endocrinology & Metabolism, 90, 3279-3286.
7. Lindsay, J.R., Nansel, T., Baid, S., et al,. (2006) Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. Journal of Clinical Endocrinology & Metabolism, 91, 447-453.
8. Hofland, L.J., &, Lamberts, S.W., (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocrine Reviews, 24, 28-47.
9. Batista, D.L., Zhang, X., Gejman, R., et al,. (2006) The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. Journal of Clinical Endocrinology & Metabolism, 91, 4482-4488.
10. Hofland, L.J., Van Der Hoek, J., Feelders, R., et al,. (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. European Journal of Endocrinology, 152, 645-654.
11. Van Der Hoek, J., Waaijers, M., van Koetsveld, P.M., et al,. (2005) Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumour cells. 87th Annual Meeting of the Endocrine Society. San Diego, CA, USA, 4-7 June, abst OR38-6.
12. Bruns, C., Lewis, I., Briner, U., et al,. (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology, 146, 707-716.
13. Colao, A., Petersenn, S., Newell-Price, J., et al,. (2012) A 12-month Phase 3 study of pasireotide in Cushing's disease. The New England Journal of Medicine, 366, 914-924.
14. Ferriman, D., &, Gallwey, J.D., (1961) Clinical assessment of body hair growth in women. Journal of Clinical Endocrinology & Metabolism, 21, 1440-1447.
15. Beck, A.T., Steer, R.A., Ball, R., et al,. (1996) Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. Journal of Personality Assessment, 67, 588-597.
16. The Diabetes Prevention Program (DPP) Research Group (2002) The diabetes prevention program (DPP): description of lifestyle intervention. Diabetes Care, 25, 2165-2171.
17. Nieman, L.K., Biller, B.M., Findling, J.W., et al,. (2008) The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 93, 1526-1540.
18. Feelders, R.A., Pulgar, S.J., Kempel, A., et al,. (2012) The burden of Cushing's disease: clinical and health-related quality of life aspects. European Journal of Endocrinology, 167, 311-326.
19. Etxabe, J., &, Vazquez, J.A., (1994) Morbidity and mortality in Cushing's disease: an epidemiological approach. Clinical Endocrinology, 40, 479-484.
20. Clayton, R.N., Raskauskiene, D., Reulen, R.C., et al,. (2011) Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. Journal of Clinical Endocrinology & Metabolism, 96, 632-642.
21. Cutler, J.A., Sorlie, P.D., Wolz, M., et al,. (2008) Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension, 52, 818-827.
22. Kearney, P.M., Whelton, M., Reynolds, K., et al,. (2005) Global burden of hypertension: analysis of worldwide data. The Lancet, 365, 217-223.
23. Rathmann, W., Haastert, B., Icks, A., et al,. (2003) High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia, 46, 182-189.
24. Shaw, J.E., Sicree, R.A., &, Zimmet, P.Z., (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research & Clinical Practice, 87, 4-14.
25. Cowie, C.C., Rust, K.F., Ford, E.S., et al,. (2009) Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care, 32, 287-294.
26. De Leo, M., Pivonello, R., Auriemma, R.S., et al,. (2010) Cardiovascular disease in Cushing's syndrome: heart versus vasculature. Neuroendocrinology, 92 (Suppl 1), 50-54.
27. Faggiano, A., Pivonello, R., Spiezia, S., et al,. (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. Journal of Clinical Endocrinology & Metabolism, 88, 2527-2533.
28. Libé, R., Morpurgo, P.S., Cappiello, V., et al,. (2005) Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery. Clinical Endocrinology, 62, 30-36.
29. Colao, A., Pivonello, R., Spiezia, S., et al,. (1999) Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. Journal of Clinical Endocrinology & Metabolism, 84, 2664-2672.
30. Pivonello, R., Faggiano, A., Lombardi, G., et al,. (2005) The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinology & Metabolism Clinics of North America, 34, 327-339.
31. Henry, R.R., Ciaraldi, T.P., Armstrong, D., et al,. (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. Journal of Clinical Endocrinology & Metabolism, 98, 3446-3453.
32. Colao, A., De Block, C., Gaztambide, M.S., et al,. (2013) Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. Pituitary, doi: 10.1007/s11102-013-0483-3. [Epub ahead of print].
33. Feelders, R.A., de Bruin, C., Pereira, A.M., et al,. (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. The New England Journal of Medicine, 362, 1846-1848.